Immunic, Inc. (IMUX) has a negative trailing P/E of -19.5, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. The forward P/E of 14.6 based on analyst estimates suggests a return to profitability is expected. Trailing earnings yield is -5.13%, forward earnings yield 6.84%. PEG 0.02 (Peter Lynch undervalued ≤1.0).
Criteria proven by this page:
Overall SharesGrow Score: 44/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2016 | -3.3 | 0.09 | 2.34 | 21,620.47 | - |
| 2017 | -4.6 | -47.55 | 4.74 | 0.00 | - |
| 2018 | -0.2 | 0.01 | 0.63 | 0.00 | - |
| 2019 | -2.2 | 0.02 | 1.28 | 0.00 | - |
| 2020 | -5.4 | 0.14 | 1.51 | 0.00 | - |
| 2021 | -2.4 | -0.06 | 1.78 | 0.00 | - |
| 2022 | -0.4 | 0.10 | 0.39 | 0.00 | - |
| 2023 | -0.7 | 0.02 | 2.30 | 0.00 | - |
| 2024 | -1.0 | 0.02 | 5.44 | 0.00 | - |
| 2025 | -8.6 | 0.23 | -124.52 | 0.00 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2016 | $-52.21 | $6.32K | $-40.97M | -648756.9% |
| 2017 | $-52.26 | $0.00 | $-52.08M | - |
| 2018 | $-39.16 | $0.00 | $-41.48M | - |
| 2019 | $-4.51 | $0.00 | $-34.83M | - |
| 2020 | $-2.81 | $0.00 | $-43.96M | - |
| 2021 | $-3.92 | $0.00 | $-92.79M | - |
| 2022 | $-4.85 | $0.00 | $-154.3M | - |
| 2023 | $-2.11 | $0.00 | $-93.61M | - |
| 2024 | $-1.00 | $0.00 | $-100.51M | - |
| 2025 | $-0.62 | $0.00 | $-97.17M | - |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-0.34 | $-0.56 – $-0.17 | $12.5M | $541.71K – $24.46M | 8 |
| 2027 | $-0.32 | $-0.40 – $-0.19 | $1M | $43.34K – $1.96M | 6 |
| 2028 | $-0.21 | $-0.49 – $0.52 | $144.65M | $6.27M – $283.04M | 6 |
| 2029 | $0.08 | $-0.02 – $0.17 | $389.29M | $16.87M – $761.71M | 4 |
| 2030 | $0.59 | $-0.14 – $1.33 | $713.46M | $30.92M – $1.4B | 2 |
